ETON Eton Pharmaceuticals Inc.

5.59
0  0%
Previous Close 5.59
Open 5.55
Price To Book 5.95
Market Cap 99,295,422
Shares 17,763,045
Volume 21,672
Short Ratio
Av. Daily Volume 137,708
Stock charts supplied by TradingView

NewsSee all news

  1. Eton Pharmaceuticals to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019

    DEER PARK, Ill., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it

  2. Eton Pharmaceuticals Announces U.S. FDA Approval of Biorphen® (phenylephrine HCI) Injection

    ~  Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~ ~ Biorphen Eliminates Need for Compounding, Reducing Risks for Unsafe Injection Practices, Medication Administration

  3. Eton Pharmaceuticals to Participate in Lake Street 3rd Annual Best Ideas Growth Conference

    DEER PARK, Ill., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL issued June 12, 2019
EM-100
Allergic conjunctivitis
NDA filing planned for 2020.
ET-102
Multiple sclerosis
NDA to be filed in 2020.
DS-100
Intractable pain
Rolling NDA filing announced March 14, 2019. However, third-party has been granted five years of market exclusivity.
DS-200
Nutritional deficiencies
aNDA (not NDA) to be filed later in 2019.
DS-300
Nutritional deficiencies
FDA Approval announced October 22, 2019.
ET-202
Injectable hospital product
NDA filing due 4Q 2019.
EM-103
Hypothyroidism
NDA filing has been submitted - noted August 6, 2019.
ET-203
Injectable hospital product
NDA filing due 4Q 2019.
EM-104
Neurological indication
PDUFA date March 17, 2020.
EM-105
Lennox-Gastaut syndrome, epilepsy

Latest News

  1. Eton Pharmaceuticals to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019

    DEER PARK, Ill., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it

  2. Eton Pharmaceuticals Announces U.S. FDA Approval of Biorphen® (phenylephrine HCI) Injection

    ~  Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~ ~ Biorphen Eliminates Need for Compounding, Reducing Risks for Unsafe Injection Practices, Medication Administration

  3. Eton Pharmaceuticals to Participate in Lake Street 3rd Annual Best Ideas Growth Conference

    DEER PARK, Ill., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that